New combo pill for fluid retention passes first Body-Processing test in healthy volunteers
NCT ID NCT07046975
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 trial enrolled 24 healthy adults to see how a new fixed-dose combination tablet containing extended-release torsemide and spironolactone is absorbed and eliminated. Participants took either the combo pill or separate tablets of each drug. Researchers measured drug levels in blood and urine to compare how the body handles the two forms. The study does not test treatment for any disease, only how the drugs behave in healthy people.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Torsemide and Spironolactone (fixed-dose combination tablet)
- What this could lead to
- If successful, this could lead to a simpler, once-daily pill for conditions like heart failure or high blood pressure that require both drugs.
- What could go wrong
- This is a small, early-stage study in healthy volunteers, not patients. It only checks how the body handles the drug, not whether it works for any disease. The combination may not prove better than taking the drugs separately.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOAVAILABILITY HEATHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sarfez Pharmaceuticals
Vienna, Virginia, 22182, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.